Mablin

Mablin is a common cancer medicament and is known to slow down the neoplastic activity of malignant cells. It is a generic and non-specific cell type alkylating antineoplastic agent that was initially created as a therapeutic medicament for chronic myeloid leukemia and has been reclassified as a generic medicament for cancer cells.

This medicament controls the burden of tumor formation and significantly slows down metastasis of cancer cells to other regions in the body. It is not able to completely impede the progress of the cancer cells, as it is incapable of reversing the overall cellular aberration effects of the cancer cells. Cytogenic abnormalities still progress, but at a much slower rate than without the medicament.

Mablin is given to cancer patients susceptible to chemotherapy and medicament induction therapy. The medicament works on a cellular level by producing Guanine-guanine strands of genetic output as it attacks the carbon strand in the mesylate group in a malignant cancer cell. This has large success rates for the target cancer cell and results in an apoptotic state. The result may also decrease overall strength as massive cellular destruction on the target area is occurring, which is evidenced by destruction of normal cells, especially in bone marrows.

Mablin is an alternative for non-operative stem cell transplantation, therefore increasing receptivity for an oncoming transplant of stem cells.

Cancer patients should have all of the proper information regarding the medicament and the proper supervision and expertise of a qualified doctor.

Mablin is a palliative medicament available in doses of 60 micrograms per body weight in kilos, with a maximum of 4 milligrams per day. For treatment of Polycythemia vera, 4 to 6 milligrams is recommended per day over 4 to 6 weeks. For thrombocythaemia, 2 to 4 milligrams per day is suggested. Conditioning therapeutic medicament plans suggest about 3.5 to 4 milligram per body weight in kilos per day, given in four doses, totaling 14 to 16 milligrams per kilo body weight.

Side effects may include general toxicity leading to fibrosis in the pulmonary tract, seizures, wasting of the muscles and organs, and cases of liver malfunction and failure. For seizures, phenytoin may be used to lessen the occurrence.

Talk with your doctor about any medicaments already being used to determine possible medicament-to-medicament interactions. Special consideration should be given to antifungal medicaments such as azole variants. This medicament is contraindicated with phenothiazines and other cancer medicaments such as cyclosporine. If contraindications of medicament is suspected, take medicament cautiously three days after last previous medicament is used. Acetaminophen is not to be used in conjunction with Mablin since it raises blood levels and may increase the risk of complicated high blood pressure.

Mablin has the following structural formula: